Nuvation Bio Inc. (NUVB) stock analysis
In our weekly check, Nuvation Bio Inc. is graded F (A to F). Of 21 checks on debt, profit, cash flow and trend: 5 pass, warnings: 3, red flags: 13.
About Nuvation Bio Inc.
Nuvation Bio Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NYSE as NUVB.
What our checks show for NUVB
Red flags
- Debt is high against equity (2.05x). That limits room in a downturn.
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- The net margin fell by 67.4 points over 5 years, to -67.4%: the company keeps less of each sale as profit.
- Weak EPS forecast
- Earnings per share fell 6.3% a year over the last 3 years.
- The company is losing money: the net margin is -67.4%.
- Free cash flow is negative (-53.6% of revenue): the business spends more cash than it brings in.
- The price swings a lot: 78.4% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 93% from a peak. Would you have held through that?
- Beta 1.73: the stock usually moves more than the market, both up and down.
- The share count grew by 56% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- A small company (market value $1.4 billion): usually riskier and followed by fewer analysts.
- The stock is still below its previous peak.
Strengths
- The gross margin is 90.6% and has risen by 90.6 points: pricing power is holding.
- Analysts expect revenue to grow about 36.3% a year over the next years.
- Analysts expect the net margin to improve by 74.7 points from today's -67.4%.
- Actively traded: about 5.4 million shares a day.
Similar companies
LBRX · ANAB · TYRA · OCUL · NTLA
Questions
What grade does Nuvation Bio Inc. (NUVB) have?
In our weekly check, Nuvation Bio Inc. is graded F (A to F). Of 21 checks on debt, profit, cash flow and trend: 5 pass, warnings: 3, red flags: 13. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of NUVB stock?
This week's biggest flags for Nuvation Bio Inc.: High debt, Weak interest cover, Margins falling. In total 16 of 21 checks show a warning or a red flag.
What does Nuvation Bio Inc. do?
Nuvation Bio Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NYSE as NUVB.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis